NCT00004494已完成1 期
Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 4
研究概览
简要总结
OBJECTIVES:
I. Determine the maximum tolerated dose of vasoactive intestinal peptide in patients with acute respiratory distress syndrome.
II. Evaluate the safety and pharmacodynamic activity of this peptide in these patients.
详细描述
PROTOCOL OUTLINE:
This is a dose escalation study.
Patients receive vasoactive intestinal peptide (VIP) IV over either 6 or 12 hours.
Cohorts of 3 patients each receive escalating doses of VIP over either 6 or 12 hours until the maximum tolerated dose is determined.
Patients are followed for 30 days.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine PatientsPainNeurologic ManifestationsSigns and SymptomsBrain DiseasesCentral Nervous System DiseasesMigraineNCT04260035Danish Headache Center21
已完成
不适用
The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) on Headache, Cranial Hemodynamic and Autonomic Symptoms in Healthy VolunteersHeadache DisordersNCT03989817Danish Headache Center12
已完成
不适用
Vasoactive Intestinal Peptide in COPDCOPDPulmonary HypertensionNCT00464932Medical University of Vienna34
已完成
1 期
Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung CancerNon Small Cell Lung CancerNCT00874588Fukushima Medical University6
已完成
1 期
Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder CancerNon-muscle Invasive Bladder CancerNCT01458847BioCis Pharma Ltd12